One of the most dreaded feelings for an investor is when the stock they just bought is overvalued, or they missed out on an undervalued opportunity by not acting fast enough.

But what if you had the insights to effectively evaluate a company like Eyepoint Pharmaceuticals Inc before investing? Investing requires a certain perspective to avoid being overly confident in a company or worried about cyclical changes. A smart way to take the guesswork out of knowing when to buy or sell Eyepoint Pharmaceuticals Inc’s stock is to have the right tools and resources as well as a clear monitoring process.

In this article, we go over a few key elements for understanding Eyepoint Pharmaceuticals Inc’s stock price such as:

• Current stock price and volume
• Stock price history
• Upgrades and downgrades from analysts
• Stock price momentum as measured by its relative strength

About Eyepoint Pharmaceuticals Inc (EYPT)

Before we jump into Eyepoint Pharmaceuticals Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Eyepoint Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s lead product candidate, EYP-1901, combines a bioerodible formulation of its Durasert technology with vorolanib, a tyrosine kinase inhibitor (TKI), which has demonstrated anti-VEGF activity. The Company has two commercial products, YUTIQ and DEXYCU. YUTIQ is a non-erodible intravitreal implant containing fluocinolone acetonide (FA) lasting for up to 36 months and is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. YUTIQ utilizes its Durasert sustained-release drug delivery technology platform. DEXYCU is an indicated for the treatment of post-operative ocular inflammation. DEXYCU utilizes its Verisome drug-delivery technology. The Company is also advancing YUTIQ 50, a six-month treatment for non-infectious uveitis affecting the posterior segment of the eye, one of the causes of blindness under a supplemental new drug application (sNDA) strategy.

Want to learn more about Eyepoint Pharmaceuticals Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Eyepoint Pharmaceuticals Inc. The AAII Stock Evaluator puts a company’s grades, charts, news, financials, valuation, ratios, filings and more at your fingertips.

Eyepoint Pharmaceuticals Inc’s Stock Price as of Market Close

As of January 17, 2023 11:47:08 AM CST, Eyepoint Pharmaceuticals Inc’s stock price was $4.44.

Eyepoint Pharmaceuticals Inc is down 11.9% from its previous closing price of $5.04.

Before the stock market closed, Eyepoint Pharmaceuticals Inc’s stock traded between $4.93 and $5.80. Currently, there are 37.34 million shares of Eyepoint Pharmaceuticals Inc stock available for purchase.

Unfortunately, Eyepoint Pharmaceuticals Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Eyepoint Pharmaceuticals Inc Stock Price History

Eyepoint Pharmaceuticals Inc’s (EYPT) price is currently up 26.86% so far this month.

During the month of January, Eyepoint Pharmaceuticals Inc’s stock price has reached a high of $5.80 and a low of $3.10.

For the year, Eyepoint Pharmaceuticals Inc has hit prices as high as $14.41 and as low as $2.19. Year to date, Eyepoint Pharmaceuticals Inc’s stock is up 26.86%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Eyepoint Pharmaceuticals Inc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of January 13, 2023, there were 1 analysts who downgraded Eyepoint Pharmaceuticals Inc’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Eyepoint Pharmaceuticals Inc’s financial health and valuation. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others.

Therefore, AAII developed a composite valuation to help resolve such issues. AAII’s Value Grade analyzes six distinct variables: price-to-sales (P/S) ratio, price-earnings (P/E) ratio, the ratio of enterprise value to earnings before interest, taxes, depreciation and amortization (EV/EBITDA), shareholder yield, price-to-book-value (P/B) ratio and price-to-free-cash-flow (P/FCF) ratio.

Eyepoint Pharmaceuticals Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Eyepoint Pharmaceuticals Inc (EYPT) by visiting AAII Stock Evaluator.

Relative Price Strength of Eyepoint Pharmaceuticals Inc

Relative price strength addresses the relationship between a stock price’s trend and the price trend of the market. This ratio is expressed as a percentage and helps investors understand a company’s momentum as well as its value. You can use relative price strength to select investments that have been outperforming the market or a specific benchmark.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. The weighted four-quarter relative price strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40%, and each of the three previous quarters are given a weighting of 20%.

As of January 13, 2023, Eyepoint Pharmaceuticals Inc has a relative price strength of 25%, which translates to a Momentum Score of 25 and is considered to be Weak.

Want to learn more about how Eyepoint Pharmaceuticals Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Eyepoint Pharmaceuticals Inc Stock Price: Bottom Line

As of January 17, 2023, Eyepoint Pharmaceuticals Inc’s stock price is $4.44, which is down 11.9% from the previous day.

At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Past returns do not guarantee future performance. Therefore, you should consider multiple ratios, fundamentals and analytics before making a decision. Whether you decide it’s a good time to buy or sell Eyepoint Pharmaceuticals Inc’s stock based on its stock price forecast is ultimately up to you.

It’s important to understand that stock prices are driven by a variety of factors, but ultimately the price at any given moment is due to the supply and demand in the market. Stock price overviews, like the one you just read, only give you a small snapshot of a company’s performance, value and momentum.

By becoming an A+ Investor subscriber, you will have full access to analytics, grades, stock screens, commentary and more so you can invest with confidence.